
  
    
      
        Introduction_NNP
        Breast_NNP cancer_NN is_VBZ the_DT most_RBS common_JJ form_NN of_IN cancer_NN in_IN women_NNS
        from_IN developed_VBN countries_NNS ._. Axillary_NNP lymph_NN node_NN status_NN is_VBZ
        widely_RB accepted_VBN as_IN an_DT important_JJ parameter_NN for_IN assessing_VBG
        prognosis_NN in_IN breast_NN cancer_NN patients_NNS ._. However_RB ,_, recurrence_NN
        and_CC death_NN also_RB occur_VB in_IN patients_NNS with_IN node-negative_JJ breast_NN
        cancer_NN (_( NNBC_NNP )_) ._. A_DT recurrence_NN rate_NN of_IN 30_CD %_NN may_MD be_VB expected_VBN
        during_IN the_DT first_JJ 5_CD years_NNS after_IN diagnosis_NN ._. Prognostic_NNP
        factors_NNS such_JJ as_IN tumour_NN size_NN ,_, tumour_NN grading_VBG ,_, hormone_NN
        receptor_NN status_NN ,_, age_NN ,_, histology_NN ,_, ploidy_NN and_CC proliferation_NN
        index_NN are_VBP used_VBN to_TO define_VB subgroups_NNS of_IN high-risk_JJ NNBC_NNP
        patients_NNS [_NN 1_CD 2_CD 3_CD 4_CD 5_CD 6_CD 7_CD 8_CD ]_NN ._. Despite_IN the_DT availability_NN of_IN
        these_DT prognostic_JJ markers_NNS ,_, high-risk_JJ NNBC_NNP patients_NNS cannot_NN be_VB
        identified_VBN with_IN sufficient_JJ accuracy_NN ._. This_DT has_VBZ led_VBN to_TO a_DT
        search_NN for_IN new_JJ and_CC possibly_RB stronger_JJR prognostic_JJ markers_NNS in_IN
        order_NN to_TO define_VB new_JJ subgroups_NNS and_CC to_TO facilitate_VB
        decision-making_NN with_IN respect_NN to_TO appropriate_JJ therapy_NN [_NN 2_CD 3_CD 9_CD
        ]_NN ._.
        Numerous_JJ reports_NNS have_VBP described_VBN the_DT correlation_NN between_IN
        amplification_NN of_IN oncogenes_NNS and_CC its_PRP$ impact_NN on_IN the_DT course_NN of_IN
        breast_NN cancer_NN disease_NN [_NN 4_CD 5_CD 6_CD 7_CD ]_NN ,_, [_NN 10_CD 11_CD 12_CD 13_CD 14_CD 15_CD 16_CD
        17_CD 18_CD 19_CD 20_CD 21_CD 22_CD 23_CD 24_CD 25_CD 26_CD 27_CD 28_CD 29_CD 30_CD 31_CD 32_CD ]_NN ._. In_IN a_DT
        meta-analysis_JJ in_IN which_WDT 29_CD studies_NNS were_VBD evaluated_VBN [_NN 33_CD ]_NN ,_,
        c-_NN 
        myc_NN amplification_NN exhibited_VBN
        significant_JJ but_CC weak_JJ associations_NNS with_IN tumour_NN grade_NN ,_, lymph_NN
        node_NN metastasis_NNS ,_, negative_JJ progesterone_NN receptor_NN status_NN and_CC
        postmenopausal_NN status_NN ._. Furthermore_RB c-_NN 
        myc_NN amplification_NN was_VBD significantly_RB
        associated_VBN with_IN risk_NN for_IN recurrence_NN and_CC death_NN ._. However_RB ,_,
        studies_NNS in_IN recent_JJ years_NNS have_VBP further_RBR shown_VBN that_IN the_DT c-_NN 
        myc_NN gene_NN participates_VBZ in_IN most_JJS aspects_NNS
        of_IN cellular_JJ function_NN ,_, including_VBG replication_NN ,_, growth_NN ,_,
        metabolism_NN ,_, differentiation_NN and_CC apoptosis_NNS [_NN 34_CD ]_NN ._.
        Amplification_NNP of_IN the_DT oncogene_NN 
        HER-_NNP 2_CD /_NN 
        neu_NN has_VBZ also_RB been_VBN shown_VBN to_TO be_VB
        indicative_JJ of_IN poor_JJ prognosis_NN in_IN breast_NN cancer_NN ._. Studies_NNS
        revealed_VBD that_IN the_DT prognostic_JJ effect_NN of_IN 
        HER-_NNP 2_CD /_NN 
        neu_NN is_VBZ stronger_JJR for_IN survival_NN than_IN for_IN
        recurrence_NN [_NN 16_CD 19_CD 20_CD 22_CD 27_CD 29_CD ]_NN ._. Furthermore_RB ,_, increased_VBD
        HER-_NNP 2_CD /_NN neu_NN levels_NNS in_IN primary_JJ tumours_NNS were_VBD associated_VBN with_IN a_DT
        poor_JJ response_NN to_TO endocrine_NN therapy_NN [_NN 5_CD 12_CD 15_CD 32_CD ]_NN ._.
        A_DT drawback_NN of_IN many_JJ studies_NNS of_IN oncogenes_NNS in_IN human_JJ breast_NN
        cancer_NN is_VBZ that_IN usually_RB only_RB one_CD oncogene_NN was_VBD evaluated_VBN ._.
        Based_VBN on_IN a_DT series_NN of_IN unselected_JJ cases_NNS ,_, in_IN the_DT present_JJ study_NN
        we_PRP examined_VBD the_DT possible_JJ influence_NN of_IN the_DT amplification_NN of_IN
        the_DT oncogenes_NNS c-_NN 
        myc_NN and_CC 
        HER-_NNP 2_CD /_NN 
        neu_NN on_IN disease-free_JJ survival_NN (_( DFS_NNP )_)
        and_CC overall_JJ survival_NN (_( OS_NNP )_) ._. Furthermore_RB we_PRP studied_VBD whether_IN
        adjuvant_NN therapies_NNS such_JJ as_IN chemotherapy_NN and_CC endocrine_NN
        treatment_NN or_CC no_DT treatment_NN at_IN all_DT had_VBN any_DT impact_NN on_IN DFS_NNP and_CC
        OS_NNP among_IN oncogene-amplified_JJ NNBC_NNP patients_NNS [_NN 1_CD 2_CD 3_CD 8_CD 9_CD 32_CD 35_CD
        36_CD 37_CD 38_CD ]_NN ._.
      
      
        Patients_NNS and_CC methods_NNS
        Among_IN 181_CD NNBC_NNP patients_NNS who_WP had_VBD undergone_VBN
        breast-conserving_JJ therapy_NN or_CC modified_VBN mastectomy_NN combined_VBN
        with_IN axillary_JJ lymphadenectomy_NN of_IN level_NN 1_CD and_CC 2_CD (_( at_IN least_JJS 10_CD
        lymph_NN nodes_NNS per_IN patient_NN had_VBD been_VBN removed_VBN )_) ,_, c-_NN 
        myc_NN and_CC 
        HER-_NNP 2_CD /_NN 
        neu_NN oncogenes_NNS were_VBD assessed_VBN
        prospectively_RB using_VBG double_JJ differential_NN PCR_NNP ._.
        Table_NNP 1_CD shows_VBZ some_DT clinical_JJ ,_, histological_JJ and_CC molecular_JJ
        parameters_NNS ._. The_DT median_JJ follow-up_JJ period_NN was_VBD 42_CD months_NNS ._.
        Postoperatively_NNP ,_, the_DT following_VBG therapies_NNS were_VBD administered_VBN
        in_IN addition_NN to_TO radiotherapy_NN :_: tamoxifen_NN 20_CD mg_NN /_NN day_NN for_IN 5_CD
        years_NNS in_IN 54_CD ._. 7_CD %_NN of_IN patients_NNS ;_: and_CC chemotherapy_NN (_( six_CD cycles_NNS of_IN
        cyclophosphamide_NN ,_, methotrexate_NN ,_, 5_CD -_: fluorouracil_NN [_NN CMF_NNP ]_NN or_CC
        four_CD cycles_NNS of_IN fluorouracil_NN ,_, epirubicin_NN ,_, cyclophosphamide_NN
        [_NN FEC_NNP ]_NN )_) in_IN 33_CD ._. 7_CD %_NN of_IN patients_NNS ._. Of_IN the_DT NNBC_NNP patients_NNS ,_, 11_CD ._. 6_CD %_NN
        did_VBD not_RB receive_VB any_DT further_JJ systemic_JJ therapy_NN ._.
        After_IN tissue_NN preparation_NN ,_, malignant_JJ and_CC normal_JJ tissues_NNS
        were_VBD kept_VBN fresh_JJ and_CC transported_VBN to_TO the_DT pathologist_NN (_( U_NNP ._. B_NNP ._. )_) ._.
        The_DT pathologist_NN dissected_VBN samples_NNS for_IN assessment_NN of_IN
        oncogenes_NNS and_CC hormone_NN receptors_NNS ._. A_DT positive_JJ receptor_NN status_NN
        was_VBD defined_VBN as_IN the_DT presence_NN of_IN more_JJR than_IN 10_CD fmol_NN /_NN mg_NN cytosol_NN
        protein_NN ._. The_DT histopathological_JJ grading_VBG was_VBD performed_VBN
        according_VBG to_TO the_DT method_NN of_IN Bloom_NNP and_CC Richardson_NNP [_NN 39_CD ]_NN ._.
        Lymph_NNP node_NN sections_NNS were_VBD stained_JJ with_IN haemotoxylin_NN and_CC
        eosin_NN ;_: immunohistochemical_JJ investigations_NNS were_VBD not_RB
        performed_VBN ._. The_DT tumour_NN tissues_NNS were_VBD stored_VBN at_IN -_: 70_CD °_NN C_NNP and_CC the_DT
        DNA_NNP was_VBD isolated_VBN using_VBG the_DT Fast_NNP Prep_NNP System_NNP (_( Bio_NNP 101_CD
        Savant_NNP ,_, Savant_NNP Instruments_NNP ,_, Inc_NNP ._. ,_, Holbrook_NNP ,_, NY_NNP ,_, USA_NNP )_) ._. Less_JJR
        than_IN 200_CD mg_NN (_( 10_CD -_: 200_CD mg_NN )_) tissue_NN was_VBD homogenized_JJ using_VBG
        FastDNA_NNP Kit_NNP in_IN the_DT Fast_NNP Prep_NNP Machine_NNP ._. After_IN preparing_VBG the_DT
        DNA_NNP ,_, the_DT content_NN was_VBD measured_VBN and_CC the_DT isolated_VBN DNA_NNP was_VBD
        stored_VBN at_IN -_: 20_CD °_NN C_NNP ._. General_JJ details_NNS for_IN the_DT double_JJ
        differential_NN PCR_NNP technique_NN ,_, reproducibility_NN and_CC clinical_JJ
        significance_NN were_VBD described_VBN previously_RB [_NN 17_CD 18_CD 28_CD 40_CD ]_NN ._. A_DT
        cutoff_NN point_NN of_IN more_JJR than_IN 2_CD ._. 0_CD average_JJ gene_NN copy_NN number_NN
        (_( AGCN_NNP )_) was_VBD considered_VBN to_TO be_VB positive_JJ for_IN 
        HER-_NNP 2_CD /_NN 
        neu_NN amplification_NN [_NN 40_CD ]_NN ._. To_TO
        calculate_VB the_DT cutoff_NN point_NN for_IN c-_NN 
        myc_NN amplification_NN ,_, all_DT NNBC_NNP patients_NNS
        were_VBD subjected_VBN to_TO Classification_NNP and_CC Regression_NNP Trees_NNP
        (_( CART_NNP )_) analysis_NN ._. A_DT cutoff_NN value_NN of_IN 2_CD ._. 1_CD AGCN_NNP for_IN c-_NN 
        myc_NN oncogene_NN led_VBN to_TO the_DT best_JJS
        distinction_NN between_IN patients_NNS ._. Fig_NNP ._. 1_LS shows_VBZ the_DT CART_NNP analysis_NN
        for_IN all_DT c-_NN 
        myc_NN values_NNS [_NN 41_CD ]_NN ._.
        Results_NNS were_VBD evaluated_VBN using_VBG the_DT SPSS_NNP system_NN (_( SPSS_NNP GmbH_NNP
        Software_NNP ,_, Munich_NNP ,_, Germany_NNP )_) ._. The_DT monoparametric_JJ survival_NN
        curves_NNS were_VBD determined_VBN using_VBG the_DT Kaplan-_NNP Meier_NNP method_NN in_IN
        order_NN to_TO estimate_VB the_DT impacts_NNS of_IN intratumoural_NN c-_NN 
        myc_NN and_CC 
        HER-_NNP 2_CD /_NN 
        neu_NN oncogene_NN amplification_NN on_IN DFS_NNP and_CC
        OS_NNP ._. Statistical_NNP deviations_NNS were_VBD defined_VBN using_VBG the_DT log-rank_JJ
        test_NN ._. Recurrence_NNP of_IN disease_NN was_VBD found_VBN at_IN the_DT following_JJ
        locations_NNS :_: local_JJ (_( 
        n_NN =_SYM 2_LS )_) ,_, contralateral_NN (_( 
        n_NN =_SYM 1_LS )_) ,_, axilla_NN (_( 
        n_NN =_SYM 2_LS )_) ,_, lung_NN (_( 
        n_NN =_SYM 1_LS )_) ,_, brain_NN (_( 
        n_NN =_SYM 1_LS )_) ,_, liver_NN (_( 
        n_NN =_SYM 1_LS )_) and_CC skin_NN (_( 
        n_NN =_SYM 1_LS )_) ._. During_IN the_DT period_NN of_IN
        observation_NN ,_, 14_CD patients_NNS died_VBD ._. In_IN order_NN to_TO derive_VB relevant_JJ
        information_NN regarding_VBG the_DT effects_NNS of_IN oncogene_NN amplification_NN
        on_IN the_DT course_NN of_IN breast_NN cancer_NN disease_NN ,_, the_DT accumulated_VBN
        values_NNS were_VBD determined_VBN after_IN postoperative_JJ periods_NNS of_IN 36_CD
        and_CC 95_CD months_NNS ._. We_PRP applied_VBD the_DT multivariate_NN Cox_NNP model_NN to_TO
        enable_VB us_PRP to_TO identify_VB independently_RB predictive_JJ parameters_NNS [_NN
        42_CD ]_NN ._. Parameters_NNP considered_VBD included_VBD the_DT oncogenes_NNS c-_NN 
        myc_NN and_CC 
        HER-_NNP 2_CD /_NN 
        neu_NN ,_, tumour_NN size_NN ,_, histopathological_JJ
        grading_VBG ,_, oestrogen_NN receptor_NN status_NN and_CC age_NN (_( <_NN 40_CD or_CC ≥_NN 40_CD
        years_NNS )_) ._. 
        P_NN <_NN 0_CD ._. 05_CD was_VBD considered_VBN

        statistically_RB significant_JJ ._.
      
      
        Results_NNS
        The_DT prevalence_NN rates_NNS for_IN amplification_NN of_IN c-_NN 
        myc_NN and_CC 
        HER-_NNP 2_CD /_NN 
        neu_NN were_VBD 21_CD ._. 5_LS %_NN and_CC 30_CD ._. 4_LS %_NN ,_,
        respectively_RB ._. Coamplification_NNP was_VBD found_VBN in_IN 22_CD patients_NNS
        (_( 12_CD ._. 2_LS %_NN ;_: Table_NNP 1_LS )_) ._. Among_IN those_DT patients_NNS with_IN c-_NN 
        myc_NN amplification_NN five_CD recurrences_NNS
        were_VBD identified_VBN (_( 5_CD /_NN 39_CD [_NN 12_CD ._. 8_CD %_NN ]_NN )_) ,_, and_CC among_IN those_DT with_IN 
        HER-_NNP 2_CD /_NN 
        neu_NN amplification_NN two_CD recurrences_NNS
        (_( 2_CD /_NN 55_CD [_NN 3_CD ._. 6_CD %_NN ]_NN )_) were_VBD identified_VBN ._. Among_IN those_DT patients_NNS in_IN whom_WP
        neither_DT c-_NN 
        myc_NN nor_CC 
        HER-_NNP 2_CD /_NN 
        neu_NN were_VBD amplified_VBN four_CD recurrences_NNS
        were_VBD found_VBN (_( 4_CD /_NN 109_CD [_NN 3_CD ._. 6_CD %_NN ]_NN )_) ,_, and_CC among_IN those_DT with_IN
        coamplification_NN of_IN both_DT oncogenes_NNS two_CD recurrences_NNS (_( 2_CD /_NN 22_CD
        [_NN 9_CD ._. 1_LS %_NN ]_NN )_) were_VBD observed_VBN ._. Four_CD patients_NNS with_IN c-_NN 
        myc_NN amplification_NN (_( 4_CD /_NN 39_CD [_NN 10_CD ._. 3_LS %_NN ]_NN )_) and_CC
        three_CD patients_NNS with_IN 
        HER-_NNP 2_CD /_NN 
        neu_NN amplification_NN (_( 3_CD /_NN 55_CD [_NN 5_CD ._. 5_LS %_NN ]_NN )_) died_VBD ._.
        Nine_CD patients_NNS who_WP lacked_VBD amplification_NN of_IN either_DT oncogene_NN
        (_( 9_CD /_NN 109_CD [_NN 8_CD ._. 3_LS %_NN ]_NN )_) and_CC two_CD patients_NNS with_IN coamplification_NN (_( 2_CD /_NN 22_CD
        [_NN 9_CD ._. 1_LS %_NN ]_NN )_) died_VBD ._.
        Using_VBG univariate_NN analysis_NN ,_, c-_NN 
        myc_NN -_: amplified_VBN cancers_NNS were_VBD
        associated_VBN with_IN a_DT significantly_RB lower_JJR DFS_NNP of_IN 85_CD ._. 3_LS %_NN ,_, as_IN
        compared_VBN with_IN 97_CD ._. 3_LS %_NN (_( 
        P_NN =_SYM 0_CD ._. 0290_CD )_) among_IN c-_NN 
        myc_NN -_: non-amplified_JJ breast_NN cancers_NNS ._.
        Ninety-five_NNP months_NNS after_IN diagnosis_NN (_( operation_NN )_) ,_, the_DT
        estimated_VBN DFS_NNP of_IN c-_NN 
        myc_NN -_: amplified_VBN cancer_NN patients_NNS was_VBD
        only_RB 85_CD ._. 3_LS %_NN ,_, as_IN compared_VBN with_IN 95_CD ._. 6_CD %_NN among_IN c-_NN 
        myc_NN -_: nonamplified_JJ patients_NNS (_( 
        P_NN =_SYM 0_CD ._. 0079_CD )_) ._. Comparison_NNP of_IN
        nonamplified_JJ cancers_NNS with_IN 
        HER-_NNP 2_CD /_NN 
        neu_NN -_: amplified_VBN cancers_NNS did_VBD not_RB reveal_VB
        any_DT significant_JJ differences_NNS with_IN regard_NN to_TO DFS_NNP (_( Fig_NNP ._.
        2_LS )_) ._.
        Multivariate_NNP analysis_NN revealed_VBD that_DT c-_NN 
        myc_NN amplification_NN and_CC tumour_NN size_NN ,_, in_IN
        contrast_NN to_TO oestrogen_NN receptor_NN status_NN ,_, grading_VBG and_CC age_NN ,_,
        were_VBD the_DT only_RB independent_JJ parameters_NNS impacting_VBG on_IN DFS_NNP
        (_( Table_NNP 2_LS )_) ._. With_IN regard_NN to_TO OS_NNP ,_, no_DT independent_JJ parameters_NNS
        were_VBD identified_VBN among_IN the_DT prognostic_JJ markers_NNS referred_VBD to_TO
        above_IN ._.
        Regarding_VBG various_JJ adjuvant_NN systemic_JJ therapies_NNS ,_, such_JJ as_IN
        chemotherapy_NN (_( CMF_NNP ,_, FEC_NNP )_) and_CC endocrine_NN therapy_NN (_( tamoxifen_NN )_) ,_,
        no_DT significant_JJ differences_NNS were_VBD observed_VBN with_IN respect_NN to_TO
        DFS_NNP and_CC OS_NNP in_IN c-_NN 
        myc_NN -_: amplified_VBN and_CC 
        HER-_NNP 2_CD /_NN 
        neu_NN -_: amplified_VBN NNBC_NNP patients_NNS in_IN
        comparison_NN with_IN non-amplified_JJ patients_NNS ._. However_RB ,_,
        significantly_RB shorter_JJR DFS_NNP and_CC OS_NNP were_VBD observed_VBN among_IN c-_NN 
        myc_NN -_: amplified_VBN patients_NNS who_WP did_VBD not_RB
        receive_VB systemic_JJ adjuvant_NN therapy_NN ._. No_DT corresponding_JJ
        associations_NNS were_VBD found_VBN among_IN 
        HER-_NNP 2_CD /_NN 
        neu_NN -_: amplified_VBN NNBC_NNP patients_NNS as_IN
        compared_VBN with_IN nonamplified_JJ patients_NNS (_( Tables_NNP 3_CD and_CC 4_LS )_) ._.
      
      
        Discussion_NNP
        Numerous_JJ clinical_JJ studies_NNS have_VBP proved_VBN axillary_JJ lymph_NN
        node_NN status_NN to_TO be_VB the_DT dominant_JJ factor_NN for_IN prognosis_NN and_CC
        prediction_NN of_IN DFS_NNP and_CC OS_NNP in_IN breast_NN cancer_NN patients_NNS ._. The_DT
        fact_NN of_IN the_DT matter_NN is_VBZ that_IN even_RB among_IN NNBC_NNP patients_NNS 25_CD -_: 30_CD %_NN
        can_MD be_VB expected_VBN to_TO progress_VB or_CC even_RB die_VB ._. The_DT advantage_NN
        conferred_VBD by_IN adjuvant_NN chemotherapy_NN or_CC endocrine_NN therapy_NN was_VBD
        examined_VBN in_IN randomized_JJ studies_NNS [_NN 2_CD 3_CD 8_CD 9_CD 35_CD 36_CD 37_CD 38_CD ]_NN ._.
        Because_IN adjuvant_NN therapies_NNS may_MD positively_RB impact_VB on_IN outcome_NN
        in_IN only_RB around_IN 15_CD %_NN ,_, the_DT costs_NNS of_IN these_DT therapies_NNS make_VBP their_PRP$
        routine_JJ application_NN in_IN all_DT NNBC_NNP patients_NNS inappropriate_JJ [_NN 1_CD
        ]_NN ._. For_IN this_DT reason_NN ,_, predictive_JJ factors_NNS that_WDT accurately_RB
        define_VB subgroups_NNS of_IN NNBC_NNP patients_NNS who_WP may_MD benefit_VB from_IN
        adjuvant_NN systemic_JJ therapy_NN would_MD be_VB a_DT great_JJ advantage_NN ._.
        In_IN the_DT present_JJ study_NN the_DT oncogenes_NNS c-_NN 
        myc_NN and_CC 
        HER-_NNP 2_CD /_NN 
        neu_NN were_VBD examined_VBN with_IN regard_NN to_TO
        their_PRP$ ability_NN to_TO predict_VB DFS_NNP ,_, OS_NNP and_CC rate_NN of_IN recurrence_NN ,_, as_RB
        well_RB as_IN mortality_NN ._. All_DT patients_NNS were_VBD randomly_RB selected_VBN from_IN
        one_CD department_NN (_( Frauenklinik_NNP Klinikum_NNP Ibbenbueren_NNP ,_,
        Ibbenbueren_NNP ,_, Germany_NNP )_) ._. C-_NNP 
        myc_NN amplification_NN was_VBD identified_VBN in_IN
        21_CD ._. 5_LS %_NN and_CC 
        HER-_NNP 2_CD /_NN 
        neu_NN amplification_NN in_IN 30_CD ._. 4_LS %_NN ._. Berns_NNP and_CC
        coworkers_NNS [_NN 12_CD 13_CD 14_CD ]_NN reported_VBD amplification_NN of_IN c-_NN 
        myc_NN in_IN 20_CD %_NN and_CC of_IN 
        HER-_NNP 2_CD /_NN 
        neu_NN in_IN 24_CD %_NN using_VBG a_DT standard_JJ southern_JJ
        blot_NN technique_NN ._. In_IN a_DT selected_VBN high-risk_JJ cohort_NN of_IN NNBC_NNP
        patients_NNS ,_, Roux-_NNP Dosseto_NNP 
        et_CC al_NN ._. [_NN 26_CD ]_NN applied_VBD the_DT same_JJ
        method_NN and_CC found_VBD prevalence_NN rates_NNS for_IN c-_NN 
        myc_NN and_CC 
        HER-_NNP 2_CD /_NN 
        neu_NN amplification_NN of_IN 25_CD %_NN and_CC 31_CD %_NN ,_,
        respectively_RB ._. Those_DT oncogenes_NNS were_VBD assessed_VBN in_IN the_DT present_JJ
        study_NN using_VBG a_DT double_JJ differential_NN PCR_NNP technique_NN [_NN 17_CD 18_CD 40_CD
        43_CD ]_NN ._. Using_VBG this_DT method_NN ,_, Brandt_NNP 
        et_CC al_NN ._. [_NN 17_CD ]_NN found_VBD c-_NN 
        myc_NN to_TO be_VB amplified_VBN in_IN 19_CD ._. 7_CD %_NN and_CC 
        HER-_NNP 2_CD /_NN 
        neu_NN in_IN 16_CD ._. 7_CD %_NN of_IN breast_NN cancers_NNS ,_,
        without_IN consideration_NN of_IN nodal_NN status_NN ;_: coamplification_NN of_IN
        those_DT oncogenes_NNS was_VBD present_JJ in_IN 7_CD %_NN ._. In_IN the_DT present_JJ study_NN ,_,
        simultaneous_JJ amplification_NN of_IN both_DT oncogenes_NNS was_VBD observed_VBN
        in_IN 12_CD ._. 2_LS %_NN ._. As_IN in_IN the_DT present_JJ investigation_NN ,_, Roux-_NNP Dosseto_NNP 
        et_CC al_NN ._. [_NN 26_CD ]_NN found_VBD that_DT c-_NN 
        myc_NN amplification_NN among_IN NNBC_NNP patients_NNS
        was_VBD significantly_RB associated_VBN with_IN earlier_JJR recurrence_NN in_IN
        univariate_NN and_CC multivariate_NN analyses_NNS ._. However_RB ,_, 
        HER-_NNP 2_CD /_NN 
        neu_NN -_: amplified_VBN NNBC_NNP patients_NNS did_VBD not_RB
        have_VB the_DT same_JJ outcome_NN ._. Accordingly_RB ,_, c-_NN 
        myc_NN amplification_NN appears_VBZ to_TO be_VB an_DT
        independent_JJ prognostic_JJ marker_NN ,_, which_WDT has_VBZ greater_JJR predictive_JJ
        power_NN than_IN does_VBZ oestrogen_NN receptor_NN status_NN and_CC tumour_NN grade_NN ._.
        As_RB early_RB as_IN 1992_CD ,_, Berns_NNP and_CC coworkers_NNS [_NN 11_CD 12_CD 14_CD ]_NN reported_VBD
        that_IN patients_NNS with_IN c-_NN 
        myc_NN -_: amplified_VBN breast_NN cancers_NNS had_VBD an_DT
        unfavourable_JJ prognosis_NN ._.
        The_DT first_JJ study_NN to_TO mention_VB possible_JJ prognostic_JJ
        importance_NN of_IN 
        HER-_NNP 2_CD /_NN 
        neu_NN gene_NN amplification_NN was_VBD reported_VBN
        in_IN 1987_CD by_IN Slamon_NNP 
        et_CC al_NN ._. [_NN 27_CD ]_NN ._. That_DT study_NN included_VBD
        187_CD patients_NNS with_IN NNBC_NNP and_CC node-positive_JJ breast_NN cancer_NN ;_: by_IN
        univariate_NN and_CC multivariate_NN analyses_NNS ,_, it_PRP revealed_VBD that_IN 
        HER-_NNP 2_CD /_NN 
        neu_NN amplification_NN correlated_JJ very_RB
        closely_RB with_IN shorter_JJR DFS_NNP and_CC OS_NNP in_IN a_DT subgroup_NN of_IN 87_CD
        node-positive_JJ patients_NNS ._. In_IN 1993_CD ,_, in_IN an_DT analysis_NN of_IN 210_CD
        patients_NNS ,_, Press_NNP 
        et_CC al_NN ._. [_NN 7_CD ]_NN found_VBD that_DT
        amplification_NN of_IN 
        HER-_NNP 2_CD /_NN 
        neu_NN correlated_JJ with_IN unfavourable_JJ
        prognosis_NN with_IN respect_NN to_TO DFS_NNP ._.
        Attempts_NNS by_IN other_JJ investigators_NNS to_TO confirm_VB these_DT
        findings_NNS were_VBD met_VBN with_IN various_JJ degrees_NNS of_IN success_NN ._. Some_DT
        studies_NNS claimed_VBD that_IN 
        HER-_NNP 2_CD /_NN 
        neu_NN status_NN was_VBD an_DT independent_JJ
        predictive_JJ factor_NN in_IN the_DT case_NN of_IN breast_NN cancer_NN ,_, whereas_IN
        other_JJ studies_NNS could_MD not_RB confirm_VB this_DT [_NN 6_CD 14_CD 16_CD 19_CD 29_CD 30_CD ]_NN ._.
        It_PRP is_VBZ certainly_RB of_IN great_JJ interest_NN to_TO the_DT clinician_NN that_IN
        only_RB two_CD out_IN of_IN five_CD studies_NNS including_VBG more_JJR than_IN 100_CD
        patients_NNS and_CC with_IN a_DT follow-up_JJ period_NN of_IN at_IN least_JJS 3_CD years_NNS
        attributed_VBD some_DT prognostic_JJ value_NN to_TO 
        HER-_NNP 2_CD /_NN 
        neu_NN amplification_NN among_IN patients_NNS with_IN
        NNBC_NNP [_NN 6_CD 7_CD 16_CD 19_CD 28_CD ]_NN ._. Almost_RB all_DT of_IN the_DT studies_NNS that_WDT
        dealt_VBD with_IN 
        HER-_NNP 2_CD /_NN 
        neu_NN status_NN and_CC DFS_NNP ,_, as_RB well_RB as_IN OS_NNP ,_,
        showed_VBD no_DT benefit_NN of_IN this_DT oncogene_NN in_IN the_DT prognosis_NN of_IN NNBC_NNP
        patients_NNS ._. In_IN a_DT survey_NN conducted_VBN by_IN Ravdin_NNP and_CC Chamness_NNP [_NN 24_CD
        ]_NN ,_, only_RB one_CD [_NN 22_CD ]_NN of_IN 11_CD studies_NNS concerning_VBG
        immunohistochemical_JJ overexpression_NN of_IN 
        HER-_NNP 2_CD /_NN 
        neu_NN indicated_VBD a_DT significant_JJ result_NN
        with_IN respect_NN to_TO OS_NNP in_IN multivariate_NN analysis_NN ._.
        In_IN the_DT present_JJ study_NN ,_, 19_CD out_IN of_IN 39_CD c-_NN 
        myc_NN -_: amplified_VBN patients_NNS received_VBD
        chemotherapy_NN ,_, 15_CD patients_NNS received_VBD endocrine_NN therapy_NN and_CC
        five_CD patients_NNS received_VBD no_DT further_JJ therapy_NN ._. The_DT greatest_JJS
        recurrence_NN rates_NNS were_VBD noted_VBN in_IN the_DT group_NN of_IN patients_NNS who_WP
        received_VBD no_DT therapy_NN (_( 20_CD %_NN )_) and_CC in_IN those_DT who_WP received_VBD
        chemotherapy_NN (_( 16_CD %_NN )_) ._. The_DT lowest_JJS recurrence_NN rate_NN of_IN 7_CD %_NN was_VBD
        seen_VBN in_IN patients_NNS treated_VBN with_IN tamoxifen_NN ._. All_DT patients_NNS who_WP
        received_VBD endocrine_NN therapy_NN (_( 
        n_NN =_SYM 99_CD )_) were_VBD characterized_VBN by_IN
        positive_JJ oestrogen_NN and_CC /_NN or_CC progesterone_NN receptor_NN status_NN ._. The_DT
        proto-oncogene_JJ c-_NN 
        myc_NN can_MD be_VB upregulated_JJ by_IN oestrogen_NN
        stimulation_NN of_IN hormone-dependent_JJ breast_NN cancer_NN cells_NNS ._.
        Endocrine_NNP therapy_NN with_IN the_DT antioestrogen_NN tamoxifen_NN can_MD
        mediate_VB the_DT downregulation_NN of_IN c-_NN 
        myc_NN ,_, culminating_VBG in_IN cell_NN cycle_NN
        arrest_NN [_NN 44_CD ]_NN ._. Berns_NNP 
        et_CC al_NN ._. [_NN 12_CD ]_NN reported_VBD that_IN 38_CD %_NN of_IN
        patients_NNS with_IN amplification_NN of_IN c-_NN 
        myc_NN or_CC with_IN coamplification_NN of_IN c-_NN 
        myc_NN and_CC 
        HER-_NNP 2_CD /_NN 
        neu_NN profited_VBD from_IN endocrine_NN therapy_NN ._.
        C-_NNP 
        myc_NN -_: amplified_VBN patients_NNS affected_VBN by_IN
        metastatic_JJ disease_NN showed_VBD a_DT tendency_NN toward_IN longer_RBR DFS_NNP with_IN
        endocrine_NN therapy_NN ,_, as_IN compared_VBN with_IN shorter_JJR DFS_NNP following_VBG
        second-line_JJ chemotherapy_NN ._. However_RB ,_, the_DT minor_JJ rate_NN of_IN
        response_NN after_IN chemotherapy_NN did_VBD not_RB correlate_VBP with_IN OS_NNP ._. The_DT
        poorer_JJR responses_NNS to_TO chemotherapy_NN among_IN patients_NNS with_IN c-_NN 
        myc_NN -_: amplified_VBN tumours_NNS in_IN the_DT present_JJ
        study_NN (_( recurrence_NN rate_NN 16_CD %_NN )_) may_MD be_VB in_IN agreement_NN with_IN
        experimental_JJ findings_NNS in_IN erythroleukaemia_NN cells_NNS that_IN the_DT
        degree_NN of_IN cis-platinum_JJ resistance_NN correlated_JJ directly_RB with_IN
        the_DT level_NN of_IN c-_NN 
        myc_NN expression_NN [_NN 45_CD ]_NN ._.
        In_IN the_DT present_JJ study_NN ,_, 26_CD out_IN of_IN 55_CD 
        HER-_NNP 2_CD /_NN 
        neu_NN -_: amplified_VBN patients_NNS received_VBD
        chemotherapy_NN ,_, 22_CD patients_NNS received_VBD endocrine_NN therapy_NN and_CC
        seven_CD patients_NNS received_VBD no_DT further_JJ therapy_NN ._. In_IN total_JJ ,_, low_JJ
        recurrence_NN rates_NNS of_IN 3_CD ._. 8_CD %_NN ,_, 4_CD ._. 5_CD %_NN and_CC 0_CD %_NN were_VBD found_VBN in_IN the_DT
        above-mentioned_JJ therapy_NN groups_NNS ,_, respectively_RB (_( Table_NNP 3_LS )_) ._.
        Compared_VBN with_IN nonamplified_JJ patients_NNS administered_VBN the_DT same_JJ
        therapies_NNS ,_, no_DT significant_JJ differences_NNS with_IN regard_NN to_TO DFS_NNP
        and_CC OS_NNP were_VBD observed_VBN ._. In_IN contrast_NN to_TO that_DT finding_VBG ,_, c-_NN 
        myc_NN -_: amplified_VBN patients_NNS not_RB
        administered_VBN adjuvant_NN systemic_JJ therapy_NN exhibited_VBN a_DT
        significantly_RB shorter_JJR DFS_NNP and_CC OS_NNP than_IN did_VBD nonamplified_JJ
        patients_NNS who_WP also_RB received_VBD no_DT adjuvant_NN systemic_JJ therapy_NN ._.
        However_RB ,_, the_DT therapy_NN groups_NNS analyzed_VBD in_IN the_DT present_JJ study_NN
        are_VBP small_JJ ,_, and_CC therefore_RB we_PRP recommend_VBP careful_JJ
        interpretation_NN of_IN the_DT findings_NNS ._.
        Higher_JJR recurrence_NN rates_NNS or_CC poor_JJ response_NN to_TO endocrine_NN
        treatment_NN with_IN tamoxifen_NN in_IN patients_NNS with_IN 
        HER-_NNP 2_CD /_NN 
        neu_NN -_: amplified_VBN hormone_NN receptor_NN
        positive_JJ tumours_NNS ,_, as_IN reported_VBN in_IN studies_NNS in_IN node-positive_JJ
        or_CC metastatic_JJ breast_NN cancer_NN [_NN 12_CD 15_CD 32_CD ]_NN ,_, were_VBD not_RB
        observed_VBN in_IN the_DT present_JJ study_NN ._. Although_IN deregulated_VBN 
        HER-_NNP 2_CD /_NN 
        neu_NN activity_NN can_MD strongly_RB stimulate_VB
        cytoplasmic_JJ signalling_VBG pathways_NNS ,_, which_WDT in_IN turn_NN impinge_NN on_IN
        c-_NN 
        myc_NN at_IN multiple_JJ levels_NNS causing_VBG its_PRP$
        deregulated_VBN expression_NN [_NN 46_CD ]_NN ,_, this_DT scenario_NN does_VBZ not_RB
        appear_VB to_TO be_VB active_JJ in_IN NNBC_NNP because_IN the_DT recurrence_NN rate_NN of_IN
        22_CD c-_NN 
        myc_NN and_CC 
        HER-_NNP 2_CD /_NN 
        neu_NN coamplified_JJ patients_NNS was_VBD only_RB 9_CD %_NN ._.
        However_RB ,_, among_IN those_DT patients_NNS in_IN whom_WP coamplification_NN of_IN c-_NN
        
        myc_NN and_CC 
        HER-_NNP 2_CD /_NN 
        neu_NN was_VBD absent_VB the_DT recurrence_NN rate_NN
        was_VBD lower_JJR (_( 4_CD /_NN 109_CD [_NN 3_CD ._. 6_CD %_NN ]_NN )_) ._. Differences_NNS in_IN the_DT numbers_NNS of_IN
        recurrences_NNS and_CC deaths_NNS can_MD be_VB accounted_VBN for_IN by_IN the_DT fact_NN
        that_IN some_DT deaths_NNS were_VBD not_RB related_VBN to_TO tumours_NNS ._.
      
      
        Conclusion_NNP
        C-_NNP 
        myc_NN amplification_NN appears_VBZ to_TO
        represent_VB a_DT prognostic_JJ marker_NN with_IN which_WDT early_JJ recurrence_NN
        may_MD be_VB predicted_VBN in_IN NNBC_NNP patients_NNS ._. C-_NNP 
        myc_NN -_: amplified_VBN NNBC_NNP patients_NNS who_WP were_VBD
        not_RB administered_VBN adjuvant_NN systemic_JJ therapy_NN suffer_VB shorter_JJR
        DFS_NNP and_CC OS_NNP ._. C-_NNP 
        myc_NN could_MD be_VB used_VBN together_RB with_IN the_DT
        tumour-associated_JJ protease_NN urokinase-plasminogen_JJ activator_NN
        and_CC its_PRP$ inhibitor_NN (_( i_NNP ._. e_SYM ._. plasminogen_NN activator_NN inhibitor-_NN 1_LS )_) ,_,
        after_IN further_JJ randomized_JJ studies_NNS have_VBP been_VBN conducted_VBN ,_, to_TO
        confirm_VB whether_IN NNBC_NNP patients_NNS should_MD receive_VB adjuvant_NN
        systemic_JJ therapy_NN [_NN 47_CD 48_CD 49_CD ]_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Abbreviations_NNP
        AGCN_NNP =_SYM average_JJ gene_NN copy_NN number_NN ;_: CART_NNP =_SYM Classification_NNP
        and_CC Regression_NNP Trees_NNP ;_: CMF_NNP =_SYM cyclophosphamide_NN ,_, methotrexate_NN ,_,
        5_CD -_: fluorouracil_NN ;_: DFS_NNP =_SYM disease-free_JJ survival_NN ;_: NNBC_NNP =_SYM
        node-negative_JJ breast_NN cancer_NN ;_: FEC_NNP =_SYM fluorouracil_NN ,_,
        epirubicin_NN ,_, cyclophosphamide_NN ;_: OS_NNP =_SYM overall_JJ survival_NN ;_: PCR_NNP =_SYM
        poly-merase_JJ chain_NN reaction_NN ._.
      
    
  
